» Articles » PMID: 21266211

Abnormalities of Angiotensin Regulation in Postural Tachycardia Syndrome

Overview
Journal Heart Rhythm
Publisher Elsevier
Date 2011 Jan 27
PMID 21266211
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Postural tachycardia syndrome (POTS) is a disorder characterized by excessive orthostatic tachycardia and significant functional disability. We previously reported that POTS patients have low blood volume and inappropriately low plasma renin activity (PRA) and aldosterone. In this study, we sought to more fully characterize the renin-angiotensin-aldosterone system (RAAS) to gain a better understanding of the pathophysiology of POTS.

Objective: The purpose of this study was to prospectively assess the plasma levels of angiotensin (Ang) peptides and their relationship to other RAAS components in patients with POTS compared with healthy controls.

Methods: Heart rate, PRA, Ang I, Ang II, Ang (1-7), and aldosterone were measured in POTS patients (n = 38) and healthy controls (n = 13) while they were consuming a sodium-controlled diet.

Results: POTS patients had larger orthostatic increases in heart rate than did controls (52 ± 3 [mean ± SEM] bpm vs 27 ± 6 bpm, P = .001). Plasma Ang II was significantly higher in POTS patients (43 ± 3 pg/mL vs 28 ± 3 pg/mL, P = .006), whereas plasma Ang I and angiotensin 1-7 [Ang-(1-7)] were similar between groups. Despite the twofold increase of Ang II, POTS patients trended to lower PRA levels than did controls (0.9 ± 0.1 ng/mL/h vs 1.6 ± 0.5 ng/mL/h, P = .268) and lower aldosterone levels (4.6 ± 0.8 pg/mL vs 10.0 ± 3.0 pg/mL, P = .111). Estimated angiotensin-converting enzyme-2 (ACE2) activity was significantly lower in POTS patients than in controls (0.25 ± 0.02 vs 0.33 ± 0.03, P = .038).

Conclusion: Some patients with POTS have inappropriately high plasma Ang II levels, with low estimated ACE2 activity. We propose that these abnormalities in Ang regulation may play a key role in the pathophysiology of POTS in some patients.

Citing Articles

Blood Pressure Regulation in Post-COVID POTS: Beyond Sinus Tachycardia.

Johansson M, Stahlberg M, Ricci F, Lewinter C, Hamrefors V, Nilsson P Hypertension. 2024; 81(12):2540-2548.

PMID: 39523946 PMC: 11578055. DOI: 10.1161/HYPERTENSIONAHA.124.23670.


Non-invasive Vagus Nerve Simulation in Postural Orthostatic Tachycardia Syndrome.

Chakraborty P, Farhat K, Morris L, Whyte S, Yu X, Stavrakis S Arrhythm Electrophysiol Rev. 2024; 12:e31.

PMID: 38173801 PMC: 10762669. DOI: 10.15420/aer.2023.20.


Evidence for Impaired Renin Activity in Postural Orthostatic Tachycardia Syndrome.

Spahic J, Mattisson I, Hamrefors V, Johansson M, Ricci F, Nilsson J J Clin Med. 2023; 12(14).

PMID: 37510775 PMC: 10380257. DOI: 10.3390/jcm12144660.


Adrenal gland response to adrenocorticotropic hormone is intact in patients with postural orthostatic tachycardia syndrome.

Laurin J, Oyewunmi O, Garland E, Gamboa A, Nwazue V, Paranjape S Auton Neurosci. 2023; 248:103105.

PMID: 37393658 PMC: 11409324. DOI: 10.1016/j.autneu.2023.103105.


Postural orthostatic tachycardia syndrome-like symptoms following COVID-19 vaccination: An overview of clinical literature.

Tv P, Tran T, Hao H, Hau N, Jain N, Reinis A Hum Antibodies. 2023; 31(1-2):9-17.

PMID: 37248893 PMC: 10357168. DOI: 10.3233/HAB-220013.


References
1.
Jacob G, Shannon J, Black B, Biaggioni I, Robertson R, Robertson D . Effects of volume loading and pressor agents in idiopathic orthostatic tachycardia. Circulation. 1997; 96(2):575-80. DOI: 10.1161/01.cir.96.2.575. View

2.
Epelman S, Tang W, Chen S, Van Lente F, Francis G, Sen S . Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol. 2008; 52(9):750-4. PMC: 2856943. DOI: 10.1016/j.jacc.2008.02.088. View

3.
Senanayake P, Moriguchi A, Kumagai H, Ganten D, Ferrario C, Brosnihan K . Increased expression of angiotensin peptides in the brain of transgenic hypertensive rats. Peptides. 1994; 15(5):919-26. DOI: 10.1016/0196-9781(94)90051-5. View

4.
Kohara K, Tabuchi Y, Senanayake P, Brosnihan K, Ferrario C . Reassessment of plasma angiotensins measurement: effects of protease inhibitors and sample handling procedures. Peptides. 1991; 12(5):1135-41. DOI: 10.1016/0196-9781(91)90070-6. View

5.
Benrud-Larson L, Sandroni P, Haythornthwaite J, Rummans T, Low P . Correlates of functional disability in patients with postural tachycardia syndrome: preliminary cross-sectional findings. Health Psychol. 2003; 22(6):643-8. DOI: 10.1037/0278-6133.22.6.643. View